The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

“We had been working in the muscarinic receptor space for almost 20 years,” says Samir Siddhanti, Neurocrine’s executive director of business development. The Neurocrine team was aware of ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Trospium is a muscarinic receptor-blocking drug that can't traverse the blood-brain barrier, so the addition of that drug to the mix reduces the unpleasant side effects in the body. Cobenfy has ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to ...